|
PL2334295T3
(pl)
|
2008-09-02 |
2017-12-29 |
Amarin Pharmaceuticals Ltd |
Kompozycja farmaceutyczna zawierająca kwas eikozapentaenowy i kwas nikotynowy oraz sposoby jej zastosowania
|
|
ES2712052T3
(es)
|
2008-10-17 |
2019-05-09 |
Cymabay Therapeutics Inc |
Métodos para reducir partículas de LDL pequeñas y densas
|
|
BRPI1014405A2
(pt)
|
2009-04-29 |
2016-04-05 |
Amarin Corp Plc |
composições farmacêuticas compreendendo epa e um agente cardiovascular e métodos de seu uso
|
|
EP3797591A1
(en)
|
2009-04-29 |
2021-03-31 |
Amarin Pharmaceuticals Ireland Limited |
Stable pharmaceutical composition and methods of using same
|
|
KR20120016677A
(ko)
|
2009-06-15 |
2012-02-24 |
아마린 파마, 인크. |
병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
|
|
SG10201405994UA
(en)
|
2009-09-23 |
2014-10-30 |
Amarin Pharmaceuticals Ie Ltd |
Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
|
|
US9719068B2
(en)
|
2010-05-06 |
2017-08-01 |
Children's Hospital Medical Center |
Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
|
|
US11712429B2
(en)
|
2010-11-29 |
2023-08-01 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
|
NZ712068A
(en)
|
2010-11-29 |
2017-03-31 |
Amarin Pharmaceuticals Ie Ltd |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
|
US11291643B2
(en)
|
2011-11-07 |
2022-04-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
|
EP2775837A4
(en)
|
2011-11-07 |
2015-10-28 |
Amarin Pharmaceuticals Ie Ltd |
METHODS OF TREATING HYPERTRIGLYCERIDEMIA
|
|
ES2891473T3
(es)
|
2012-01-06 |
2022-01-28 |
Amarin Pharmaceuticals Ie Ltd |
Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
|
|
HUE053111T2
(hu)
|
2012-06-29 |
2021-06-28 |
Amarin Pharmaceuticals Ie Ltd |
Módszerek kardiovaszkuláris események veszélyének csökkentésére sztatin terápiával kezelt alanyban eikozapentaénsav-etilészter alkalmazásával
|
|
WO2014074552A2
(en)
|
2012-11-06 |
2014-05-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
|
|
US9814733B2
(en)
*
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
|
US10272058B2
(en)
|
2014-03-20 |
2019-04-30 |
Cymabay Therapeutics, Inc. |
Treatment of intrahepatic cholestatic diseases
|
|
UA120756C2
(uk)
|
2014-03-20 |
2020-02-10 |
Сімабей Терапьютікс, Інк. |
Лікування внутрішньопечінкових холестатичних захворювань
|
|
DK3129018T3
(da)
|
2014-04-11 |
2020-01-20 |
Cymabay Therapeutics Inc |
Behandling af NAFLD og NASH
|
|
EP3712254A1
(en)
|
2014-05-28 |
2020-09-23 |
Children's Hospital Medical Center |
Methods and systems for converting precursor cells into gastric tissues through directed differentiation
|
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
|
WO2015195662A1
(en)
|
2014-06-16 |
2015-12-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
|
|
EP3207123A1
(en)
|
2014-10-17 |
2017-08-23 |
Children's Hospital Center D/b/a Cincinnati Children's Hospital Medical Center |
In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
|
|
KR20170131644A
(ko)
*
|
2015-03-26 |
2017-11-29 |
티3디 테라퓨틱스, 인크. |
인단 아세트산 유도체를 사용한 간 질환의 치료 방법
|
|
CN115025079A
(zh)
|
2015-04-28 |
2022-09-09 |
普罗诺瓦生物医药挪威公司 |
结构增强的含硫脂肪酸在预防和/或治疗非酒精性脂肪性肝炎中的用途
|
|
US10940125B2
(en)
|
2015-09-18 |
2021-03-09 |
Duke University |
Methods and compositions for the treatment of steatosis-associated disorders
|
|
WO2017139708A1
(en)
|
2016-02-10 |
2017-08-17 |
Synlogic, Inc. |
Bacteria engineered to treat nonalcoholic steatohepatitis (nash)
|
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
|
CA3016641A1
(en)
|
2016-05-05 |
2017-11-09 |
Children's Hospital Medical Center |
Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
|
|
GB201614455D0
(en)
*
|
2016-08-24 |
2016-10-05 |
Univ Oxford Innovation Ltd |
Biomarkers
|
|
EP3534976A4
(en)
|
2016-11-04 |
2020-09-16 |
Children's Hospital Medical Center |
LIVER ORGANOID DISEASE MODELS AND METHODS OF MANUFACTURING AND USING THEREOF
|
|
US10493363B2
(en)
*
|
2016-11-09 |
2019-12-03 |
Activision Publishing, Inc. |
Reality-based video game elements
|
|
WO2018106628A1
(en)
|
2016-12-05 |
2018-06-14 |
Children's Hospital Medical Center |
Colonic organoids and methods of making and using same
|
|
TWI762634B
(zh)
|
2017-05-05 |
2022-05-01 |
大陸商上海赫普化醫藥技術有限公司 |
胺基-芳基-苯甲醯胺化合物及其使用方法
|
|
WO2018213663A1
(en)
|
2017-05-19 |
2018-11-22 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject having reduced kidney function
|
|
US10512622B2
(en)
|
2017-07-14 |
2019-12-24 |
Cymabay Therapeutics, Inc. |
Treatment of intrahepatic cholestatic diseases
|
|
CN111093705A
(zh)
|
2017-09-13 |
2020-05-01 |
诺华股份有限公司 |
包含fxr激动剂的组合
|
|
EP3701953A4
(en)
*
|
2017-10-27 |
2021-06-16 |
Samyang Corporation |
COMPOSITION FOR PREVENTING OR RELIEVING NON-ALCOHOLIC HEPATIC STEATOSIS
|
|
IL275002B2
(en)
|
2017-12-06 |
2024-04-01 |
Basf As |
Fatty acid antecedents for the treatment of nonalcoholic fatty liver disease
|
|
US11058661B2
(en)
|
2018-03-02 |
2021-07-13 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
|
|
PT4056176T
(pt)
|
2018-09-24 |
2024-05-27 |
Amarin Pharmaceuticals Ie Ltd |
Métodos de redução do risco de eventos cardiovasculares num indivíduo
|
|
MX2021005725A
(es)
*
|
2018-11-16 |
2021-07-21 |
Cymabay Therapeutics Inc |
Tratamiento de la obesidad y sus complicaciones.
|
|
KR20210092754A
(ko)
*
|
2018-11-16 |
2021-07-26 |
사이머베이 쎄라퓨틱스, 인코퍼레이티드 |
Nafld 및 nash의 병용 치료
|
|
WO2021097034A1
(en)
|
2019-11-14 |
2021-05-20 |
Cymabay Therapeutics, Inc. |
Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases
|
|
US20210145774A1
(en)
|
2019-11-14 |
2021-05-20 |
Cymabay Therapeutics, Inc. |
Treatment of alcoholic liver disease
|
|
CN115811972A
(zh)
*
|
2020-05-13 |
2023-03-17 |
拓臻制药公司 |
肝脏病症的组合治疗
|
|
WO2022225896A1
(en)
|
2021-04-21 |
2022-10-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of heart failure
|
|
CA3214214A1
(en)
*
|
2021-05-11 |
2022-11-17 |
Genfit |
Ppar-agonists for use in the treatment of liver failure
|
